New precision therapy aims to intercept AML relapse before it starts
NCT ID NCT06664879
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 26 times
Summary
This study tests whether giving targeted treatments based on a person's specific genetic mutations can prevent early relapse in acute myeloid leukemia (AML). It is designed for patients whose cancer shows signs of returning at a molecular level. The approach uses a platform trial to assign tailored therapies and monitor safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.